Skip to main navigation

Home
Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Year

April 26, 2022

Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership

April 20, 2022

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

April 5, 2022

Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

April 4, 2022

Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

March 30, 2022

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

March 24, 2022

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

March 21, 2022

Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

March 21, 2022

Athira Pharma to Participate in Two Upcoming Investor Conferences

March 20, 2022

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

March 17, 2022

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

Pagination

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
…
Next page
Last page

Displaying 71 - 80 of 135

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

info@athira.com

© Athira Pharma, Inc. All rights reserved.